BVS Economia da Saúde

Immunotherapy-based first-line treatment of intermediate- and poor-risk advanced renal cell carcinoma: number needed to treat and cost of preventing an event from the perspective of the Brazilian private healthcare system

Oliveira, Ana Paula Casagrande Drozda; Roubik, Camila Finardi; Dyer, Matthew T. D; Neusquen, Lucienne Pereira Del Grossi; Marcolino, Miriam Allein Zago; Ribeiro, Rodrigo Antonini; May, Jessica R.

J. bras. econ. saúde (Impr.); 13 (3), 2021

Objective: To perform an analysis over time of the number needed to treat (NNT) and the cost of preventing an event (COPE) for nivolumab + ipilimumab (NIVO+IPI) and pembrolizumab + axitinib (PEMBRO+AXI) as first-line treatments for advanced renal cell carcinoma patients with intermediate or poor-risk, un...

Carcinoma de Células Renais, Axitinibe, Custos e Análise de Custo, Custos de Cuidados de Saúde, Nivolumabe

Texto completo (link principal) Texto completo (link alternativo)

Hospital expenses and liver disease in Brazil

Schwambach, Karin Hepp; Becker, Matheus William; Paz, Adriana Aparecida; Linch, Graciele Fernanda da Costa; Weis, Alísia Helena; Blatt, Carine Raquel.

J. bras. econ. saúde (Impr.); 12 (2), 2020

Objective: This study aims at describing the values and morbimortality of hospital admissions for liver disease in the Brazilian public health system. Methods: The study was carried out in the DATASUS, for a period of five years. The number, causes, time, mortality rate and values of hospitalizations in ...

Custos Hospitalares, Custos de Cuidados de Saúde, Hepatopatias, Sistema Único de Saúde

Texto completo (link principal) Texto completo (link alternativo)

Sequential biological therapies in metastatic colorectal cancer (mCRC): a cost comparison analysis for wildtype RAS mCRC patients in Brazil

Weschenfelder, Rui Fernando; Tsuchiya, Carolina Terumi; Kim, Hellen Soo Jin; Simões, Jairo Amorim; La Scala, Cintia Sayuri Kurokawa.

J. bras. econ. saúde (Impr.); 8 (1), 2016

Objective: To compare the treatment costs of different sequences of regimens including monoclonal antibodies in metastatic colorectal cancer (CRCm) treatment for the Brazilian Supplementary Healthcare System. Methods: Sixteen scenarios were analyzed, each one comparing a sequence of bevacizumab TML plu...

Neoplasias Colorretais, Custos de Cuidados de Saúde, Saúde Suplementar

Texto completo

Resultados: 3

Immunotherapy-based first-line treatment of intermediate- and poor-risk advanced renal cell carcinoma: number needed to treat and cost of preventing an event from the perspective of the Brazilian private healthcare system

Hospital expenses and liver disease in Brazil

Sequential biological therapies in metastatic colorectal cancer (mCRC): a cost comparison analysis for wildtype RAS mCRC patients in Brazil

Queremos sua opinião!